Amgen to present data on Repatha and observational studies at ESC Congress 2015 Amgen today announced that it’ll present six abstracts in the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 2 in London. Data will be presented evaluating RepathaTM , a proprotein convertase subtilisin/kexin type 9 inhibitor accepted in the European Union for the treatment of individuals with uncontrolled cholesterol who require extra intensive low-density lipoprotein cholesterol reduction tadalafiljelly.net . This has been a historic yr for Amgen’s cardiovascular franchise with multiple regulatory milestones, like the recent EU acceptance of Repatha, the initial PCSK9 inhibitor approved by a regulatory agency in the global world, and we’re thrilled to continue the momentum with fresh data being presented at this year’s ESC Congress, stated Sean E.
We look forward to studying the combination of talimogene laherparepvec and KEYTRUDA in head and neck cancer, and to advancing our collaboration in metastatic melanoma into a Phase 3 scientific trial. .. Merck and Amgen expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study Amgen and Merck , known as MSD outside the U.S. In addition, the ongoing companies announced a global, randomized Stage 3 trial analyzing the combination in sufferers with regionally or distantly metastatic melanoma is being initiated. As announced previously, the compounds are getting studied in a Stage 1, open-label trial in this individual populace.